DehydroheliobuphthalminCAS# 103001-05-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 103001-05-4 | SDF | Download SDF |
PubChem ID | 91884890 | Appearance | Powder |
Formula | C22H20O8 | M.Wt | 412.4 |
Type of Compound | Lignans | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | dimethyl (3E)-2-(1,3-benzodioxol-5-ylmethyl)-3-(1,3-benzodioxol-5-ylmethylidene)butanedioate | ||
SMILES | COC(=O)C(CC1=CC2=C(C=C1)OCO2)C(=CC3=CC4=C(C=C3)OCO4)C(=O)OC | ||
Standard InChIKey | MHPJAZYITXHVOI-VIZOYTHASA-N | ||
Standard InChI | InChI=1S/C22H20O8/c1-25-21(23)15(7-13-3-5-17-19(9-13)29-11-27-17)16(22(24)26-2)8-14-4-6-18-20(10-14)30-12-28-18/h3-7,9-10,16H,8,11-12H2,1-2H3/b15-7+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Dehydroheliobuphthalmin has significant neuroprotective activities against glutamate- induced neurotoxicity. |
Dehydroheliobuphthalmin Dilution Calculator
Dehydroheliobuphthalmin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4248 mL | 12.1242 mL | 24.2483 mL | 48.4966 mL | 60.6208 mL |
5 mM | 0.485 mL | 2.4248 mL | 4.8497 mL | 9.6993 mL | 12.1242 mL |
10 mM | 0.2425 mL | 1.2124 mL | 2.4248 mL | 4.8497 mL | 6.0621 mL |
50 mM | 0.0485 mL | 0.2425 mL | 0.485 mL | 0.9699 mL | 1.2124 mL |
100 mM | 0.0242 mL | 0.1212 mL | 0.2425 mL | 0.485 mL | 0.6062 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Acetaminophen
Catalog No.:BCC5269
CAS No.:103-90-2
- 4'-Methylacetanilide
Catalog No.:BCC8714
CAS No.:103-89-9
- Phenylacetic Acid
Catalog No.:BCC8349
CAS No.:103-82-2
- N-Methylbenzylamine
Catalog No.:BCN1790
CAS No.:103-67-3
- Scutebarbatine M
Catalog No.:BCN8327
CAS No.:960302-92-5
- Benzyl cinnamate
Catalog No.:BCN5042
CAS No.:103-41-3
- Ethyl cinnamate
Catalog No.:BCN5044
CAS No.:103-36-6
- Methyl cinnamate
Catalog No.:BCN5043
CAS No.:103-26-4
- Monobenzone
Catalog No.:BCC3818
CAS No.:103-16-2
- H-DL-Phg-OH
Catalog No.:BCC3317
CAS No.:103-01-5
- Trelagliptin succinate
Catalog No.:BCC2015
CAS No.:1029877-94-8
- INCB28060
Catalog No.:BCC3793
CAS No.:1029712-80-8
- Alterlactone
Catalog No.:BCN7261
CAS No.:1030376-89-6
- MK-4305
Catalog No.:BCC1760
CAS No.:1030377-33-3
- CTCE 9908
Catalog No.:BCC6366
CAS No.:1030384-98-5
- Ethyl 3-(pyridin-2-ylamino)propanoate
Catalog No.:BCC8973
CAS No.:103041-38-9
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- MK-8245
Catalog No.:BCC2299
CAS No.:1030612-90-8
- AS 2034178
Catalog No.:BCC7996
CAS No.:1030846-42-4
- Bakuchiol
Catalog No.:BCN5845
CAS No.:10309-37-2
- 2-Amino-6-chloropurine
Catalog No.:BCC8540
CAS No.:10310-21-1
- Kinetensin (human)
Catalog No.:BCC5845
CAS No.:103131-69-7
- ABT-046
Catalog No.:BCC1326
CAS No.:1031336-60-3
- 4-(4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile hydrobromide
Catalog No.:BCC8648
CAS No.:103146-26-5
Evaluation of lignans from Heliopsis helianthoides var. scabra for their potential antimetastatic effects in the brain.[Pubmed:25479041]
J Nat Prod. 2014 Dec 26;77(12):2641-50.
Two new arylbenzofuran-type neolignans, 1"-dehydroegonol 3"-methyl ether (1) and egonol 3"-methyl ether (2), and four known lignan derivatives, namely, helioxanthin (3), (7E)-7,8-Dehydroheliobuphthalmin (4), heliobuphthalmin (5), and 7-acetoxyhinokinin (6), were isolated from a chloroform-soluble partition of the methanol extract of the fresh roots of Heliopsis helianthoides var. scabra. These six compounds were evaluated in vitro in terms of their ability to inhibit the various steps involved in brain tumor metastasis formation. Compounds 3 and 4 inhibited the migration of both melanoma and brain endothelial cells, and 3 also reduced the adhesion of melanoma cells to the brain endothelium. Furthermore, 3 and 4 additionally enhanced the barrier function of the blood-brain barrier and the expression of the tight junction protein ZO-1 at the junctions of the endothelial cells. These findings suggest that 3 and 4 may have the potential to interfere with different steps of brain metastasis formation and to enhance the barrier function of cerebral endothelial cells.